Sareum logo

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

Contact Sareum via their website

News archive

19/12/2017   Patent Grants in Japan and China for Sareum's TYK2 Inhibitors...more
23/10/2017   Sareum issues final results and highlights for 2017 year end...more
19/06/2017   Sareum Presents at the International Cancer Cluster Showcase 2017...more
31/05/2017   Sareum notes Sierra Oncology announcement of patents for Chk1 inhibitor SRA737...more
10/04/2017   Sareum joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code